Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Insulin detemir(NN-304)].

K Kaku1

  • 1Diabetes & Endocrinology Division, Kawasaki Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 20, 2001
PubMed
Summary
This summary is machine-generated.

Normalizing blood glucose is key to preventing diabetic complications. A new long-acting insulin analog, NN-304, offers a flatter action profile for improved basal insulin replacement.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

Decreased plasma aldosterone levels in patients with type 2diabetes mellitus: A possible pitfall in diagnosis of primary aldosteronism.

Diabetes & metabolism·2019
Same author

Bayesian reconstruction of a vancomycin-resistant Enterococcus transmission route using epidemiologic data and genomic variants from whole genome sequencing.

The Journal of hospital infection·2019
Same author

Marked elevation of plasma procalcitonin levels in patients with diabetic ketoacidosis: A possible useful diagnostic biomarker.

Diabetes & metabolism·2019
Same author

Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.

Transplantation proceedings·2018
Same author

Preoperative Muscle Volume Predicts Graft Survival After Pancreas Transplantation: A Retrospective Observational Cohort Study.

Transplantation proceedings·2018
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Context:

  • Diabetic complications are linked to blood glucose control.
  • Insulin therapy requires tailored time-action profiles for optimal glycemic management.
  • Current long-acting insulin formulations have limitations.

Purpose:

  • To introduce NN-304, a novel soluble long-acting insulin analog.
  • To highlight NN-304's potential to overcome drawbacks of existing insulin formulations.
  • To explore NN-304's clinical advantages, including a flatter time-action profile.

Summary:

  • NN-304 (B29Lys-myristoyl. des-B30 human insulin) is a new class of soluble long-acting insulin analog.
  • Its prolonged metabolic action is achieved through fatty acid association with albumin.
  • NN-304 aims to provide a more physiological basal insulin action.

Related Experiment Videos

Impact:

  • NN-304 may offer improved clinical utility in managing diabetes.
  • Potential for reduced disadvantages compared to current long-acting insulin options.
  • May better replicate natural basal insulin secretion patterns.